Document:

<PAGE>

                                                                     Exhibit 4.2

                             SUPPLEMENTAL INDENTURE

--------------------------------------------------------------------------------

                      FISHER SCIENTIFIC INTERNATIONAL INC.

                    6 1/8% SENIOR SUBORDINATED NOTES DUE 2015

                            ------------------------

                          FIRST SUPPLEMENTAL INDENTURE
                         DATED AS OF SEPTEMBER 20, 2006

                            ------------------------

                    THE BANK OF NEW YORK TRUST COMPANY, N.A.,
                                   AS TRUSTEE

--------------------------------------------------------------------------------

<PAGE>

      FIRST SUPPLEMENTAL INDENTURE, dated as of September 20, 2006, between
Fisher Scientific International Inc., a Delaware corporation (the "Company"),
and The Bank of New York Trust Company, N.A. (the "Trustee").

      WHEREAS, the Company and the Trustee are parties to an Indenture, dated as
of July 15, 2005 (the "Indenture"), pursuant to which the Company issued its
6 1/8% Senior Subordinated Notes Due 2015 (the "Notes");

      WHEREAS, the Board of Directors of the Company has determined that it is
in the best interests of the Company to authorize and approve amendments (the
"Proposed Amendments") to the Indenture;

      WHEREAS, Section 9.2 of the Indenture provides that the Company and the
Trustee may amend the Indenture and the Notes with the written consent of the
Holders of not less than a majority in aggregate principal amount of the Notes
then outstanding;

      WHEREAS, the Company has distributed a Consent Solicitation Statement,
dated September 6, 2006 (the "Solicitation Statement"), and accompanying Consent
Form to the Holders of the Notes in connection with the Proposed Amendments as
described in the Solicitation Statement;

      WHEREAS, the Holders of not less than a majority in aggregate principal
amount of the Notes outstanding have approved the Proposed Amendments to the
provisions of the Indenture; and

      WHEREAS, the execution and delivery of this instrument have been duly
authorized and all conditions and requirements necessary to make this instrument
a valid and binding agreement have been duly performed and complied with;

      NOW, THEREFORE, for and in consideration of the premises and other good
and valuable consideration, receipt and sufficiency of which are hereby
acknowledged, it is mutually covenanted and agreed, for the equal proportionate
benefit of all Holders of the Notes, as follows:

ARTICLE 1. AMENDMENT OF SECTION 4.18 AND SECTION 4.20

      Section 1.01. The first paragraph of Section 4.18 of the Indenture is
hereby amended by inserting the following clause at the end of the second to
last sentence:

          "; provided however, that the filing of the reports specified in
          Sections 13 and 15(d) of the Exchange Act by an entity that is the
          direct or indirect parent of the Company will satisfy the requirements
          of this Section 4.18 so long as such entity is an obligor or guarantor
          on the indenture securities; and provided further that the reports of
          such entity will not be required to include condensed consolidating
          financial information for the Company in a footnote to the financial
          statements of such entity."

      Section 1.02. Section 4.20 of the Indenture is hereby amended to read in
its entirety as follows:

          "EFFECT OF CREDIT RATING ON CERTAIN COVENANTS. The Company's
          obligation to comply with the covenants set forth in Sections 4.3,
          4.4, 4.5, 4.6, 4.7, 4.9, 4.10, 4.11, 4.12 and Section 5.1(a)(ii)
          hereof shall be suspended (and the failure of the Company to comply
          with such covenants shall not constitute an Event of Default pursuant
          to Section 6.1 hereof) at any time when, but only for so long as, the
          Notes have a Minimum Rating from either S&P or Moody's.
          Notwithstanding the foregoing, in the event that the suspended
          covenants have not been terminated and the credit rating of the Notes
          has been downgraded from a Minimum Rating, the suspended covenants
          shall be reinstated in full force and effect. On the first date on
          which the Notes have a Minimum Rating from both S&P and Moody's, the
          covenants of the Company set forth in Sections 4.3, 4.4, 4.5, 4.6,
          4.7, 4.9, 4.10, 4.11, 4.12 and Section 5.1(a)(ii) hereof shall cease
          to apply to the Company as of and at all times after such date,
          regardless of whether the Notes fails to maintain a Minimum Rating
          from either S&P or Moody's thereafter."

<PAGE>

ARTICLE 2. MISCELLANEOUS

      Section 2.01. It shall be a condition precedent to the Company's ability
to take the actions contemplated by this Supplemental Indenture that the merger
of a wholly owned subsidiary of Thermo Electron Corporation with and into the
Company, with the Company surviving as a wholly owned subsidiary of Thermo
Electron Corporation shall have been consummated.

      Section 2.02. On the date hereof, the Indenture shall be supplemented and
amended in accordance herewith, and this First Supplemental Indenture shall form
a part of the Indenture for all purposes, and the Holder of every Security
heretofore or hereafter authenticated and delivered under the Indenture shall be
bound thereby. The Trustee accepts the trusts created by the Indenture, as
amended and supplemented by this First Supplemental Indenture, and agrees to
perform the same upon the terms and conditions of the Indenture, as amended and
supplemented by this First Supplemental Indenture.

      Section 2.03. All capitalized terms used and not defined herein shall have
the respective meanings assigned to them in the Indenture.

      Section 2.04. This First Supplemental Indenture shall become effective as
of the date hereof at such time as executed counterparts of this First
Supplemental Indenture have been delivered by each party hereto to the other
party hereto.

      Section 2.05. Each of the Company and the Trustee hereby confirms and
reaffirms the Indenture in every particular except as amended and supplemented
by this First Supplemental Indenture. Except as supplemented and amended hereby,
all provisions in the Indenture and the First Supplemental Indenture shall
remain in full force and effect.

      Section 2.06. All covenants and agreements in this First Supplemental
Indenture by the Company or the Trustee shall bind their respective successors
and assigns, whether so expressed or not.

      Section 2.07. In case any provisions in this First Supplemental Indenture
shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or
impaired thereby.

      Section 2.08. Nothing in this First Supplemental Indenture express or
implied, shall give to any Person, other than the parties hereto and their
successors under the Indenture and the Holders of the Notes, any benefit or any
legal or equitable right, remedy or claim under the Indenture.

      Section 2.09. The parties may sign any number of copies of this First
Supplemental Indenture. Each signed copy shall be an original, but all of them
together represent the same agreement. One signed copy is enough to prove this
First Supplemental Indenture.

      Section 2.10. The Trustee shall not be responsible in any manner
whatsoever for or in respect of the validity or sufficiency of this First
Supplemental Indenture or for or in respect of the recitals contained herein,
all of which are made solely by the Company.

      Section 2.11. In entering into this First Supplemental Indenture, the
Trustee shall be entitled to the benefit of every provision of the Original
Indenture and the Notes relating to the conduct or affecting the liability or
affording protection to the Trustee, whether or not elsewhere herein so
provided.

      Section 2.12. All provisions of this First Supplemental Indenture shall be
deemed to be incorporated in, and made a part of, the Indenture; and the
Indenture, as amended and supplemented by this First Supplemental Indenture,
shall be read, taken and construed as one and the same instrument and all
provisions in the Indenture and the Notes shall remain in full force and effect.

      Section 2.13. All covenants and agreements in this First Supplemental
Indenture by the Company shall be

<PAGE>

binding upon and accrue to the benefit of their respective successors. All
covenants and agreements in this First Supplemental Indenture by the Trustee
shall be binding upon and accrue to the benefit of its successors.

      Section 2.14. This First Supplemental Indenture shall be governed by, and
construed in accordance with, the laws of the State of New York but without
giving effect to applicable principles of conflicts of law to the extent that
the application of the laws of another jurisdiction would be required thereby.

      IN WITNESS WHEREOF, the parties have caused this First Supplemental
Indenture to be duly executed as of the date first written above.

                             FISHER SCIENTIFIC INTERNATIONAL INC.

                             By: /s/ Kevin Clark
                                 -----------------------------------------------
                                 Name: Kevin Clark
                                 Title: Vice President & Chief Financial Officer

                             THE BANK OF NEW YORK TRUST COMPANY, N.A.

                             By: /s/ Peter  M. Murphy
                                 -----------------------------------------------
                                 Name: Peter  M. Murphy
                                 Title: Vice President<PAGE>

                                                                  Exhibit 10.3.1

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                LICENSE AGREEMENT

                                 by and between

                           WYETH HOLDINGS CORPORATION

                                       and

                                 BIOVEX LIMITED

                                   dated as of

                                  April 1, 2005

<PAGE>

                                LICENSE AGREEMENT

THIS AGREEMENT is made as of April 1, 2005 (the "Effective Date") by and between
Wyeth Holdings Corporation, having a place of business at Five Giralda Farms,
Madison, New Jersey, 07940 ("Licensor"), and Biovex Limited, (company number
3480520), having its registered office at 70 Milton Park, Abingdon, Oxford OX14
4RX England ("Licensee").

     Licensor is the owner of the Licensed Patents, as defined below.

     Licensee wishes to obtain a license under the Licensed Patents, to develop,
have developed, make, have made, use, offer to sell, sell and have sold, import
and have imported, Licensed Products and perform Licensed Services, as defined
below.

     Licensor is willing to grant such a license to Licensee on the terms and
conditions of this Agreement.

     Licensor and Licensee have therefore agreed as follows.

1. DEFINITIONS

     The following terms shall have the meanings indicated in this Agreement:

     1.1. "Agreement" means this Agreement, including all Schedules hereto.

     1.2. "Affiliate" means any Person controlled by, controlling, or under
common control with either Licensee or Licensor. For this purpose, "control"
means direct or indirect beneficial ownership of at least fifty percent (50%)
interest in the voting stock (or the equivalent) of such Person or having the
right to direct, appoint or remove a majority or more of the members of its
board of directors (or their equivalent), or having the power to control the
general management of such Person, by contract, law or otherwise.
Notwithstanding the foregoing, the term "Affiliate" shall not include Persons in
which a Party or its Affiliates owns a majority of the ordinary voting power to
elect a majority of the board of directors or other governing body, but is
restricted from electing such majority by contact or otherwise, until such time
as such restrictions are no longer in effect.

     1.3. "Applicable Percentage" means [**] percent ([**]%).

     1.4. "Bankruptcy Event" means, with respect to a specified Person, (a) the
filing by such Person in any court or agency, pursuant to any statute or
regulation of any state or country, a petition in bankruptcy or insolvency or
for reorganization or for the appointment of a receiver or trustee of such
Person or of its assets, (b) the filing against such Person of an involuntary
petition for any bankruptcy or insolvency proceeding which petition is not
dismissed within ninety (90) days after filing, (c) the making by such Person of
an assignment for the benefit of its creditors, (d) the taking of possession of
any material part of the assets of such Person by a lien holder or other
encumbrancer, or (e) the levy or enforcement of any distress, execution or other
process upon or against any of the material assets of such Person.

                                       1

<PAGE>

     1.5. "Confidential Information" means, with respect to any Party
("Disclosing Party"), any information relating to the Licensed Product(s) or
Improvements that is disclosed in writing or by email to the other Party
("Receiving Party") during the term of this Agreement, but shall not include
information that:

          1.5.1. the Receiving Party or an Affiliate owned or controlled prior
     to receipt from the Disclosing Party, or

          1.5.2. is or becomes public through no breach of this Agreement by the
     Receiving Party or any Affiliate thereof, or

          1.5.3. is hereafter developed by the Receiving Party or an Affiliate
     independent of any disclosure from the Disclosing Party as evidenced by
     competent written evidence, or

          1.5.4. the Receiving Party or an Affiliate obtains from a third Person
     not under a confidentiality obligation to the Disclosing Party.

     1.6. "Effective Date" has the meaning given to it in the Preamble.

     1.7. "Improvements" means any information, patentable or otherwise,
developed or acquired (by license or otherwise, provided in the case of
acquisition that the terms of the acquisition do not prohibit Licensee from
making the grant set forth in Section 2.1.5) by Licensee during the term of this
Agreement and which relates to improvements to inventions disclosed in the
Licensed Patents as follows:

          "Improvements in Area A" means patentable and non-patentable [**] to
     regions of the HSV-1 and/or HSV-2 genome other than regions represented by
     the [**] gene or between the [**] and [**] sites on the [**] corresponding
     to [**] that result in improved [**] in and [**] neoplastic cells conceived
     under and/or reduced to practice by BioVex during the term of this
     Agreement;

          "Improvements in Area B" means patentable and non-patentable [**]
     within regions of the HSV-1 and/or HSV-2 genome represented by the [**]
     gene or between the [**] and [**] sites on the [**] corresponding to [**]
     that result in improved [**] in and [**] neoplastic cells conceived under
     and/or reduced to practice by BioVex during the term of this Agreement.

     1.8. "Licensed Patents" means United States patent application Serial
Number 08/686631 filed July 24, 1996 and any divisional, continuation or
continuation-in-part thereof or substitute therefor, any foreign patent
applications corresponding to any such patent applications claiming priority
from such patents and applications, and any U.S. or foreign patent or the
equivalent thereof issuing therefrom and any reissue, re-examination, renewal,
supplementary protection certificate or extension thereof.

     1.9. "Licensed Product(s)" means any product which would, or the
development, manufacture, use, sale or importation of which product would,
absent the license granted by

                                        2

<PAGE>

Licensor to Licensee herein, infringe any Valid Claim in any Licensed Patent in
a country where a Licensed Patent subsists.

     1.10. "Licensed Service(s)" means any commercial research, development or
manufacturing services provided to a third Person, the provision of which
utilizes or embodies any process, product or discovery claimed by one or more
Valid Claims of any Licensed Patent in a country where a Licensed Patent
subsists.

     1.11. "Net Sales" shall mean the actual gross amount invoiced by Licensee
or its Affiliate or any sublicensee (as defined in Section 2.1.1(d)) for sales
or other commercial disposition of a Licensed Product, or provision of a
Licensed Service, to a third Person customer (including any distributor as
defined in Section 2.1.1 (b)), less the following deductions with respect to
such sales or services:

               a) any rebates, quantity, trade and cash discounts, and other
          usual and customary discounts to customers;

               b) compulsory payments and rebates, actually paid or deducted;

               c) retroactive price reductions, credits or allowances actually
          granted upon rejections or returns of Licensed Products, including for
          recalls or damaged goods;

               d) freight, postage, shipping and insurance charges actually
          allowed or paid for delivery of Licensed Products, to the extent
          included in the gross sales price;

               e) sales taxes, excise taxes, use taxes, import/export duties or
          other governmental charges actually due or incurred with respect to
          such sales, including without limitation value-added taxes;

               f) discounts and performance discounts to the extent that such
          discounts are associated with the Licensed Products together with
          other products of Licensee and its Affiliates, and to the extent that
          such discounts cannot be attributed only to the Licensed Products.
          Such discounts and performance discounts will be allocated to the
          Licensed Products on a reasonable pro rata basis (based on the amount
          of the sales of products by Licensee and its Affiliates prior to
          discount); and

               g) charge-back payments and rebates granted to managed health
          care organizations or to federal, state and local governments, their
          respective agencies, purchasers or reimbursers;

all as incurred in the ordinary course of business in type and amount consistent
with good industry practice and determined in accordance with generally accepted
accounting principles on a basis consistent with Licensee's audited consolidated
financial statements.

                                        3

<PAGE>

For sake of clarity and avoidance of doubt, sales by Licensee, its Affiliates or
any sublicensee defined in Section 2.1.1 (d) of a Licensed Product to a
distributor defined in Section 2.1.1 (b) of such Licensed Product in a given
country shall be considered a sale to a third Person customer.

Any Licensed Products used as samples or used for clinical or other research
purposes and for donations shall not be included in Net Sales.

     1.12. "Party" means each party to this Agreement and their respective
successors and permitted assigns.

     1.13. "Person" means any natural person or legal entity.

     1.14. "Phase II" means any controlled clinical study involving the use of a
Licensed Product in human patients designed primarily to obtain preliminary data
on the effectiveness of a specific therapy involving the use of a Licensed
Product in human patients.

     1.15. "Phase III" means any Phase IIb/III clinical study involving a
Licensed Product designed to have adequate statistical power to meet the
requirements for regulatory approval by regulatory authorities either in the
United States, European Union, or Japan.

     1.16. "Royalty Payments" is defined in Section 3.1.4.

     1.17. "Territory" means all countries in the world.

     1.18 "Valid Claim" means any claim of any issued and unexpired patent that
has not been held permanently revoked, deemed unenforceable or invalid by a
decision of a court or other government agency of competent jurisdiction, which
decision is unappealable or unappealed within the time allowed for appeal.

2. LICENSE

     2.1. Grant of License. Licensor hereby grants to Licensee for the term of
this Agreement a non-exclusive, royalty bearing license under the Licensed
Patents, with the limited right to grant sublicenses only as set forth in
Section 2.1.1, to develop, have developed, make, have made, use, offer to sell,
sell, have sold, import and have imported, Licensed Products and to provide
Licensed Services in the Territory. In addition to the other terms and
conditions of this Agreement, the license granted hereby is subject to the
following:

          2.1.1. Sublicensing. Notwithstanding anything herein to the contrary,
     Licensee shall have the right to grant sublicenses only to (a) Licensee's
     Affiliates, (b) any distributor of Licensed Products pursuant to a bona
     fide arm's length distribution agreement between such distributor and
     Licensee, (c) any subcontractor that performs all or a portion of the
     manufacturing of Licensed Products pursuant to a bona fide arm's length
     manufacturing agreement between such subcontractor and Licensee, or (d) any
     third Person that enters into a bona fide license agreement with Licensee
     to make, use, sell or promote Licensed Products; provided, however, that
     Licensee shall be responsible for the operations of any sublicensee
     relevant to this Agreement as if such operations were carried out by
     Licensee itself, including

                                        4

<PAGE>

     (without limitation) the payment of any royalties or other payments
     provided for hereunder. All sublicenses granted hereunder shall be
     consistent with and subject to the terms and conditions of this Agreement.
     Licensee shall notify Licensor of any such sublicense and provide Licensor
     with a copy of any such sublicense agreement within ten (10) days of the
     execution thereof.

          2.1.2. Restriction on other Rights. No right or license is granted to
     Licensee in or to any right or interest of Licensor that is not
     specifically set forth in this Agreement.

          2.1.3. Due Diligence. Licensee shall comply with all applicable laws
     and regulations. Licensee shall be responsible for obtaining all regulatory
     approvals required for the manufacture and sale of Licensed Products.
     Licensee shall provide Licensor (i) prompt written notice of all regulatory
     approvals for Licensed Products in the Territory, and (ii) on an annual
     basis with a summary of the development status of the Licensed Products and
     Licensed Services. Licensee shall use reasonable commercial efforts to
     research, develop and bring to market Licensed Products and Licensed
     Services; provided that Licensee shall always be free to stop development
     or put development of any Licensed Product or Licensed Service on hold
     without termination of this Agreement. In case Licensee provides written
     notice to Licensor that the development of all Licensed Products and
     Licensed Services is stopped or put on hold, all obligations of the
     Licensee hereunder shall cease or shall be suspended respectively, until
     such time as Licensee restarts development of a Licensed Product, except
     for the following: Section 2.1.3 first and third sentences, Sections, 3, 5,
     6, 7 and 8.

          2.1.4. Licensee shall inform Licensor within ten (10) business days
     upon achievement of any milestone described in Section 3.1.3.

          2.1.5. Improvements. Licensee hereby grants to Licensor (i) a [**]
     non-exclusive, [**] license [**] to the Improvements in Area A, and (ii) a
     [**] license [**] to the Improvements in Area B. Licensee shall keep
     Licensor currently and generally advised in writing of all Improvements,
     and shall provide Licensor with a written report thereof not less than once
     each calendar year. Upon request of Licensor, Licensee shall finish to
     Licensor one copy of all available documents relating to such Improvements.

3. PAYMENTS

     3.1. Payments. Licensee shall make the following payments to Licensor as
consideration for the rights granted by Licensor hereunder:

          3.1.1. Licensing Fee. Upon execution of this Agreement, Licensee shall
     pay within ten (10) days to Licensor a non-refundable licensing fee of One
     Hundred Twenty Five Thousand U.S. Dollars (U.S. $125,000) in immediately
     available funds to an account designated in writing by Licensor.

          3.1.2. Annual Maintenance Fee. Within thirty (30) days of each annual
     anniversary of the Effective Date, Licensee shall pay to Licensor Twenty
     Five Thousand U.S. Dollars

                                        5

<PAGE>

     (U.S. $25,000) creditable against payments under Section 3.1.4 in the
     Calendar year in which such annual maintenance fee is paid.

          3.1.3. Milestone Payments. Licensee shall pay to Licensor the
     following non-refundable milestone payments, to be paid only once, at the
     time when a Licensed Product reaches a milestone described below:

               (i) upon initiation of the first Phase II clinical trial by or on
          behalf of Licensee (for the purposes of this Section, initiation shall
          mean the first administration of the first Licensed Product in a
          clinical trial): Two Hundred Thousand U.S. Dollars (U.S. $200,000);

               (ii) upon initiation of the first Phase II clinical trial by or
          on behalf of Licensee (for the purposes of this Section, initiation
          shall mean the first administration of the second and each subsequent
          Licensed Product in a clinical trial): One Hundred Thousand U.S.
          Dollars (U.S. $100,000);

               (iii) upon initiation of a Phase III clinical trial of each
          Licensed Product by or on behalf of Licensee (for the purposes of this
          Section, initiation shall mean the first administration of each
          Licensed Product in such a trial): Three Hundred Thousand U.S. Dollars
          (U.S. $300,000); and

               (iv) upon receiving an approval for marketing anywhere in the
          Territory of each Licensed Product: Five Hundred Thousand U.S. Dollars
          (U.S. $500,000).

     Each such milestone payment shall be due and payable to Licensor within
     thirty (30) days of the date such milestone is achieved (whether achieved
     by or on behalf of Licensee or any of its Affiliates or sublicensees).
     Licensee shall remit to Licensor each such milestone payment in immediately
     available funds to an account designated in writing by Licensor.

          3.1.4. Royalties. Licensee shall pay or cause to be paid to Licensor a
     royalty equal to the Applicable Percentage of all Net Sales of any Licensed
     Product or Licensed Service by Licensee or any of its Affiliates, or
     permitted sublicensees ("Royalty Payments") on a country-by-country basis.
     No multiple royalties shall be payable because a Licensed Product or
     Licensed Service, its manufacture, use or sale is or shall be covered by
     more than one Valid Claim of a patent included in the Licensed Patents or
     more than one patent under the Licensed Patents. Royalty shall only be
     payable once in respect of each Licensed Product. Royalty Payments shall be
     made in accordance with Sections 3.4 and 3.5.

     3.2. Records. During the Term of this Agreement and for three (3) years
thereafter, Licensee shall (and shall cause its Affiliates and permitted
sublicensees to) keep complete and accurate records of sales of Licensed
Products and Licensed Services and such other matters as may affect the
determination of any amount payable to Licensor hereunder in sufficient detail
to enable a recognized international firm of certified public or chartered
accountants engaged by Licensor to determine any amounts payable to Licensor
under this Agreement.

                                        6

<PAGE>

Licensee shall (and shall cause its Affiliates and permitted sublicensees to)
permit certified public accountants engaged by Licensor, at Licensor's expense
(except as provided below), to examine not more than once in any twelve-month
period per Person its books, ledgers, and records during regular business hours
for the purpose of and to the extent necessary to verify any report required
under this Agreement or the accuracy of any amount payable hereunder for a three
(3) year period after the royalty period to which such records relate. Should
any examination conducted by Licensor or its representatives pursuant to the
provisions of this paragraph result in an increase of more than five percent
(5%) of any payment due Licensor hereunder, Licensee, in addition to any amounts
that may be due Licensor, shall be obligated to reimburse any out-of-pocket
expenses incurred by Licensor with respect to such examination within thirty
(30) days after receipt of an invoice therefor from Licensor.

     3.3. Royalty Reports. Within sixty (60) days after March 31, June 30,
September 30 and December 31 of each year, Licensee shall deliver to Licensor a
true and accurate report, giving such particulars of the business conducted by
Licensee, its Affiliates and permitted sublicensees during the preceding quarter
under this Agreement as are pertinent to an accounting for any Royalty Payments
hereunder. Each such report will contain at least the following information: the
number and kind of Licensed Products and Licensed Services (including where
permitted the identity of each Person to whom Licensed Services are sold) sold
in each country, total gross invoice amounts for each such Licensed Product and
Licensed Service, deductions applicable to Net Sales thereof, a calculation of
total amount due to Licensor for the relevant period, the exchange rate used to
convert gross invoice amounts and deductions applicable to Net Sales thereof in
each country. All payments shall be made in United States dollars.

     3.4. Payments. Within sixty (60) days of the end of each calendar quarter
in which any Net Sales occur, Licensee shall calculate the Royalty Payments owed
to Licensor and shall remit to Licensor the amount owed to Licensor in
immediately available funds to an account designated in writing by Licensor. For
purposes of determining when a sale of Licensed Product occurs, the sale shall
be deemed to occur on the date of invoice to the purchaser of the Licensed
Product.

     3.5 Taxes. If laws or regulations require withholding with respect to
payments made by Licensee of any taxes imposed upon Licensor on account of any
royalties and advance payments, paid under this Agreement, such taxes shall be
deducted by Licensee as required by law from such remittable royalty and advance
payment and shall be paid by Licensee to the proper tax authorities. Official
receipts of payment of any withholding tax shall be secured and sent to Licensor
as evidence of such payment. The Parties shall exercise their best efforts to
ensure that any withholding taxes imposed are reduced as far as possible under
the provisions of any relevant tax treaty.

     3.6 Overdue Payments. Payments not paid within seven (7) days of the
respective time period set forth in this Section 3 shall bear interest at a rate
of two percent (2%) above the London Interbank Offered Rate (LIBOR) from the due
date until paid in full.

                                        7

<PAGE>

4. PROTECTION OF INTELLECTUAL PROPERTY RIGHTS

     4.1. Patent Prosecution/Patent Costs. Licensor shall be responsible for the
prosecution, maintenance, renewal, extension and defense of all Licensed Patents
in its sole discretion and at its expense.

     4.2. Infringement by Third Persons. Licensee shall promptly advise Licensor
in writing of any infringement or suspected infringement of any of the rights
under the Licensed Patents. In the case of any infringement of any Licensed
Patent by any third Person (an "Infringer") during the term of this Agreement,
Licensor shall have the right under Licensor's control and at Licensor's expense
to prosecute any third Person infringement of the Licensed Patents. Subject to
Licensor's control of any such proceeding, Licensee shall have the right, at its
own expense and using counsel of its choosing, to participate in such
proceeding. Licensee shall assist as reasonably requested in taking any such
action against any such Infringer at Licensor's expense, unless Licensee has
stopped the development of all Licensed Products or has put the development of
all Licensed Products on hold. Any amount recovered by or reimbursed to Licensor
as a result of any action taken by Licensor under this Section 4.2 (including,
without limitation, from any settlement or other voluntary disposition thereof)
shall be retained by Licensor.

     4.3. Patent Marking. Licensee shall use appropriate patent marking on
Licensed Products where legally permissible. Licensee shall register or record
this Agreement in any country if Licensor's legal or beneficial interest in the
Licensed Patents would be prejudiced in such country by a failure to register.

     4.4. Patent Term Restoration. Licensor and Licensee shall cooperate in
obtaining patent term restoration in the United States or its equivalent in the
Territory where applicable to the Licensed Patents, including 35 U.S.C. 156 and
its foreign counterparts.

5. INDEMNIFICATION; ETC.

     5.1. Indemnification.

          5.1.1. Except as provided in Section 5.1.2, Licensee shall indemnify,
     defend and hold harmless Licensor, its Affiliates, and their respective
     directors, officers, managers, employees and agents and their respective
     successors, heirs and assigns (each a "Licensor Indemnitee"), against any
     liability, damage, deficiency, loss, cost or expense of any kind (including
     reasonable attorneys' fees and expenses of litigation) (each a "Liability")
     incurred by or imposed upon any Licensor Indemnitee as a result of any
     third party claim made or suit brought against a Licensor Indemnitee to the
     extent the same is relating to (a) any death, illness, personal injury,
     property damage or improper business practices arising out of the
     development, manufacture, sale, use or other disposition of any Licensed
     Product or provision of any Licensed Service (whether based on negligence
     or other tort, warranty, strict liability, or any other theory) or (b) any
     breach of this Agreement by Licensee.

          5.1.2. Except as provided in Section 5.1.1, Licensor shall indemnify,
     defend and hold harmless Licensee, its Affiliates, and their respective
     directors, officers,

                                        8

<PAGE>

     managers, employees and agents and their respective successors, heirs and
     assigns (each a "Licensee Indemnitee"), against any liability, damage,
     deficiency, loss, cost or expense of any kind (including reasonable
     attorney's fees and expenses of litigation) (each a "Liability") incurred
     by or imposed upon any Licensee Indemnitee as a result of any third party
     claim made or suit brought against a Licensee Indemnitee to the extent the
     same is relating to any breach of this Agreement by Licensor.

          5.1.3. A party's obligation to defend, indemnify and hold harmless is
     conditioned upon the indemnified party providing to the indemnifying party
     immediate notice of any such liability and providing all reasonable
     assistance in defending against such Liability.

          5.1.4. This Section 5.1 shall survive expiration or termination of
     this Agreement.

     5.2. Warranty Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT,
LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTY INCLUDING, WITHOUT LIMITATION, ANY
IMPLIED WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A
PARTICULAR PURPOSE WITH RESPECT TO ANY OF THE LICENSED PATENTS OR ANY LICENSED
PRODUCTS OR LICENSED SERVICES OR OTHERWISE AND HEREBY DISCLAIMS THE SAME. EXCEPT
AS PROVIDED BELOW, LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTY THAT THE
MANUFACTURE, USE OR SALE OF ANY LICENSED PRODUCT OR PROVISION OF ANY LICENSED
SERVICE WILL NOT INFRINGE ANY PATENT OR OTHER RIGHT OF ANY PARTY OR THIRD PERSON
AND HEREBY DISCLAIMS THE SAME.

     5.3. Representations and Warranties of Licensor.

          5.3.1. Licensor hereby represents, warrants and covenants to Licensee
     that Licensor has the full right and authority to execute and perform this
     Agreement and the execution and performance of this agreement by Licensor
     will not conflict with, cause a default under or violate any existing
     contractual obligation that may be owed by Licensor to any third Person.

          5.3.2. Licensor has not previously assigned, transferred, conveyed or
     otherwise encumbered its right, title and interest in the Licensed Patents.

          5.3.3. Licensor shall maintain the Licensed Patents for the duration
     of this Agreement

          5.3.4. To Licensor's knowledge as of the Effective Date, each of the
     Licensed Patents is valid.

     5.4. Representations and Warranties of Licensee. Licensee hereby
represents, warrants and covenants to Licensor that Licensee has the full right
and authority to execute and perform this Agreement and the execution and
performance of this agreement by Licensee

                                        9

<PAGE>

will not conflict with, cause a default under or violate any existing
contractual obligation that may be owed by Licensee to any third Person.

     5.5. Insurance. In the event that Licensee is conducting clinical trials
using Licensed Products or manufacturing and supplying Licensed Products,
Licensee shall obtain product liability insurance citing Licensor as an
interested party under terms which are similar to that obtained by other
companies comparable to Licensee for products similar to such Licensed Products
and used in similar circumstances.

6. TERM AND TERMINATION

     6.1. Term. This Agreement will be effective as of the Effective Date and
will remain in effect until all Valid Claims in all Licensed Patents have
expired on a country-by country basis. Licensee shall have no obligation to make
Royalty Payments with respect to the Net Sales of a Licensed Product or
provision of a Licensed Service if (a) all Valid Claims in all Licensed Patents
applicable to the development, manufacture, use, sale or importation of such
Licensed Product or provision of such Licensed Service have expired in each
country in which such Licensed Product is used, sold or imported or such
Licensed Service is provided and (b) all Valid Claims in all Licensed Patents
applicable to the development, manufacture, use, sale or importation of such
Licensed Product or provision of such Licensed Service have expired in each
country in which such Licensed Product is manufactured or such Licensed Service
is provided. For the avoidance of doubt, Licensee shall be obligated to make
Royalty Payments with respect to products that are Licensed Products in
countries in which they are manufactured even if such products are used, sold or
imported in or into countries in which they are not Licensed Products.

     6.2. Termination by Licensor.

          6.2.1. Termination for Cause. Licensor shall have the right to
     terminate this Agreement and the license granted hereunder upon the
     happening of the following events:

               (i) Licensee fails to pay or cause to be paid any payment which
          has become due to Licensor under this Agreement and has not cured such
          non-payment within thirty (30) days after written notice from Licensor
          to Licensee specifying such non-payment.

               (ii) Licensee is in breach of or default under any material
          provision of this Agreement other than a payment obligation referred
          to in Section 6.2.1 (i) and has not cured such breach or default
          within sixty (60) days after written notice from Licensor to Licensee
          specifying the nature of such breach or default.

          6.2.2. Termination after Challenge. If Licensee or any of its
     Affiliates directly or indirectly makes, files, maintains or supports any
     claim, demand, lawsuit, cause of action or other action or proceeding,
     including without limitation by reexamination, opposition, interference,
     declaratory judgment proceeding or invalidity or nullity proceeding,
     alleging that a Licensed Patent is invalid or

                                       10

<PAGE>

     unenforceable, Licensor may immediately upon written notice to Licensee
     terminate this Agreement.

     Notwithstanding anything to the contrary in this Agreement, and provided
     that the discovery request, subpoena or court order was not initiated by or
     on behalf of Licensee or any of its Affiliates and does not result from
     legal proceedings that were initiated or supported by or on behalf of the
     Licensee or any of its Affiliates, if Licensee or any of its Affiliates or
     sublicensees is subject to a discovery request, subpoena or court order
     relating to one or more of the Licensed Patents that might be violative, or
     might lead to any action or proceeding that might be a violation, of this
     Section 6.2.2, Licensee, such Affiliate or such sublicensee shall provide
     prompt notice to Licensor of such discovery request, subpoena or court
     order such that Licensor may take any steps necessary to obtain a
     protective or other order. If reasonable efforts to obtain such protective
     or other order are unsuccessful, of if further delay in compliance with
     such discovery request, subpoena or court order is reasonably likely to
     result in a finding of contempt, Licensee, such Affiliate or such
     sublicensee may comply with such discovery request, subpoena or court
     order.

     6.3. Bankruptcy Event. Licensor may, at its option, terminate this
Agreement immediately upon notice to Licensee if a Bankruptcy Event occurs with
respect to the Licensee.

     6.4. Termination by Licensee. Licensee shall have the right to terminate
this agreement immediately upon one hundred and twenty (120) days written notice
to Licensor given after the complete and final cessation of, with the intention
never to resume, any and all activities relating to the development,
manufacture, commercialization, marketing or sale of Licensed Products and
Licensed Services by Licensee, its Affiliates, distributors, subcontractors or
permitted sublicensees.

     6.5. Effect of Termination.

          6.5.1. Upon termination of this Agreement for any reason, nothing
     herein shall be construed to release either Party from any obligation that
     matured prior to the effective date of such termination.

          6.5.2. Upon termination of this Agreement for any reason, any
     sublicense granted hereunder with respect to which the sublicensee is not
     then in breach or default shall continue as a direct license between the
     sublicensee and the Licensor on the terms of this Agreement, provided that
     the sublicensee agrees in writing, within thirty (30) days after
     termination of this Agreement, to be bound by the terms of this Agreement.

          6.5.3. The provisions of Sections 3.2 (Records), 3.5 (Taxes), 3.6
     (Overdue Payments), 4.2 (Infringement by Third Persons) (but only with
     respect to infringement occurring prior to termination), 5.1
     (Indemnification), 5.2 (Warranty Disclaimer), and 8 (General) shall survive
     termination of this Agreement for any reason.

                                       11

<PAGE>

          6.5.4. Licensee may, after termination of this Agreement, sell all
     Licensed Products which are in inventory at the time of termination, and
     complete and sell Licensed Services which Licensee can clearly demonstrate
     were in the process of being provided at the time of such termination,
     provided that Licensee shall pay to Licensor any Royalty Payments due on
     the sale of such Licensed Products or provision of such Licensed Services
     and shall submit reports, in accordance with this Agreement.

7. CONFIDENTIALITY

     7.1. Confidentiality. Subject to Section 7.2. below, during the term of
this Agreement neither Party shall use or disclose any Confidential Information
received by it pursuant to this Agreement without the prior written consent of
the other.

     7.2. Permitted Disclosure. Nothing contained in this Section shall be
construed to restrict the Parties from disclosing Confidential Information to
the extent that is reasonably required: (i) for legal, regulatory, tax, or
customs reasons, (ii) for audit purposes, (iii) by court or other government
order, or (iv) from using such Confidential Information as is reasonably
necessary to perform acts permitted by, or to exploit rights granted under this
Agreement.

8. GENERAL

     8.1. Assignment. This Agreement shall be binding upon and shall inure to
the benefit of each Party and each Party's respective transferees, successors
and assigns, provided, however, that Licensee shall not have the right to assign
this Agreement or its rights or obligations hereunder to any other Person
without the prior written consent of the Licensor other than as set forth in the
next sentence. Licensee may assign this Agreement and all of its rights and
obligations under this Agreement to any third Person who acquires all or
substantially all of Licensee's assets (or those of a separate business unit of
Licensee by merger, sale of assets or stock, or otherwise, or to any third
Person who acquires all or substantially all of Licensee (or a separate business
unit of Licensee) by merger, sale of assets or stock, or otherwise. Licensee
shall provide Licensor with a copy of any such executed assignment agreement.
Any purported assignment in violation of the provisions of this Section 8.1
shall be null and void.

     8.2. Publicity. Neither Party shall issue any news release or other public
announcement relating to this Agreement, including any of its terms, without the
prior written approval of the other Party. Once the text or substance of any
announcement has been so approved, it may be repeated without further approval.

     8.3. Use of Name. Except as may be agreed to by the Parties pursuant to
Section 8.2, neither Party shall use the name of the other in connection with
this Agreement, the Licensed Patents, the Licensed Products the Licensed
Services or any related matter in any press releases, public announcements or
other publicity or advertising materials without the prior written approval of
the other Party.

                                       12

<PAGE>

     8.4. Entire Agreement/Amendments. This Agreement constitutes the entire and
only agreement between the Parties relating to Licensed Patents, and all prior
negotiations, representations, agreements and understandings are superseded
hereby. No agreements amending, altering or supplementing the terms hereof may
be made except by means of a written document signed by a duly authorized
representative of each Party.

     8.5. Notices. Any notice, communication or payment required or permitted to
be given or made hereunder shall be in writing and, except as otherwise
expressly provided in this Agreement, shall be deemed given or made and
effective (i) when delivered personally; or (ii) when delivered by telex or
telecopy (if not a payment); or (iii) when received if sent by overnight
express; or (iv) upon confirmation of receipt if mailed by certified or
registered mail, postage prepaid and return receipt requested, in each case
addressed to Parties at their address stated below, or to such other address as
such Party may designate by written notice in accordance with the provisions of
this Section 8.5.

LICENSEE:     Biovex Limited
              70 Milton Park
              Abingdon, Oxford
              OX14 4RX
              England
              Fax: +44 1235 441901
              Attention: Vice President, Business Development

LICENSOR:     Wyeth Holdings Corporation
              Five Giralda Farms
              Madison, New Jersey 07940
              Fax: (973) 660-7050
              Attention: General Counsel

with copy to: Wyeth Pharmaceuticals
              500 Arcola Road, CC-3
              Collegeville, PA 19426
              Fax: (484) 865-9301
              Attention: Senior Vice President, Global Business Development

     8.6. Governing Law; Jurisdiction. This Agreement shall be construed and
enforced in accordance with the domestic substantive laws of The State of New
York and the United States of America without regard to any choice or conflict
of laws rule or principle that would result in the application of the domestic
substantive law of any other jurisdiction other than, in regard to any question
affecting the construction or effect of any patent, the law of the jurisdiction
under which such patent is granted. This Agreement shall not be subject to (a)
the United Nations Conventions on Contracts for the International Sale of Goods;
(b) the 1974 Convention on the Limitation Period in the International Sale of
Goods (the "1974 Convention"); or (c) the Protocol amending the 1974 Convention,
done at Vienna April 11, 1980. Any legal or other action hereunder shall be
brought exclusively in the U.S. Federal courts of New York. The Parties consent
to the personal jurisdiction and venue of such courts in the event of such
action. The

                                       13

<PAGE>

Parties hereby consent to waive any constitutional, statutory or common law
right of trial by jury and of forum non-conviens.

     8.7. Limitation of Liability. EXCEPT FOR THE LIABILITY ARISING OUT OF
SECTION 5.1, EACH PARTY'S AGGREGATE LIABILITY FOR ALL DAMAGES OF ANY KIND
RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED THE AMOUNT
PAID OR PAYABLE BY LICENSEE TO LICENSOR UNDER THIS AGREEMENT. The foregoing
limitations shall apply to all claims and actions of any kind, whether based on
contract, tort (including but not limited to negligence), or any other grounds.

     8.8. Headings. Headings included herein are for convenience only, and shall
not be used to construe this Agreement.

     8.9. Independent Contractors. For the purposes of this Agreement and all
services to be provided hereunder, each Party shall be, and shall be deemed to
be, an independent contractor and not an agent, partner, joint venturer or
employee of the other Party. Neither Party shall have authority to make any
statements, representations or commitments of any kind, or to take any action
which shall be binding on the other Party, except as may be explicitly provided
for herein or authorized in writing.

     8.10. Severability. If any provision of this Agreement shall be found by a
court of competent jurisdiction to be void, invalid or unenforceable, the same
shall either be reformed to comply with applicable law or stricken if not so
conformable, so as not to affect the validity or enforceability of this
Agreement.

     8.11. Force Majeure. Neither Party shall be responsible or liable to the
other Party for nonperformance or delay in performance of any terms or
conditions of this Agreement due to acts or occurrences beyond the control of
the nonperforming or delayed Party, including, but not limited to, acts of God,
acts of government, wars, riots, strikes or other labor disputes, shortages of
labor or materials, fires, and floods, provided the nonperforming or delayed
Party provides to the other Party written notice of the existence of and the
reason for such nonperformance or delay.

     8.12. No Waiver. Failure of either Party to enforce a right under this
Agreement shall not act as a waiver of that right or the ability to later assert
that right relative to the particular situation involved or to terminate this
Agreement arising out of any subsequent default or breach.

                                       14

<PAGE>

     8.13. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall constitute an original document, but all of
which shall constitute the same agreement.

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
by their duly authorized representatives as of the date first set forth above.

BIOVEX LIMITED                          WYETH HOLDINGS CORPORATION

By: /s/ Robert Coffin                   By: /s/ Robert F. Smith
    ---------------------------------       ------------------------------------
Name: Robert Coffin                     Name: Robert F. Smith
Title: Chief Scientific Officer         Title: Vice President

By: /s/ Tony Mills
    ---------------------------------
Name: Tony Mills
Title: Vice President, Business Development

                                       15

<PAGE>

                                   Schedule 1

                                LICENSED PATENTS

<TABLE>
<CAPTION>
     COUNTRY        APPLICATION   Filing Date      Patent                      Issue Date
     -------        -----------   -----------      ------                      ----------
<S>                 <C>           <C>              <C>                         <C>
USA                 60/001602     July 27, 1995
USA                 08/686631     July 24, 1996    5,824,318                   October 20, 1998
PCT                 96/12281      July 24, 1996
Australia           67139/96      July 25, 1996    725557                      January 25, 2001
Canada              2227860       July 25, 1996    Application still pending
Europe*             96927257.4    July 25, 1996    841943                      September 3, 2003
Israel              118942        July 24, 1996    118942                      December 15, 2002
Israel-divisional   135726        April 18, 2000   Application still pending
S. Africa           96/6287       July 26, 1996    96/6287                     May 27, 1998
Taiwan              85/09120      July 26, 1996    Abandoned
</TABLE>

*    Nationalized patents in Austria, Belgium, Denmark, Finland, France,
     Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Netherlands,
     Portugal, Spain, Sweden & Switzerland

                                      -16-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]